Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(28 sites)
China
Beijing Chao-Yang Hospital, Capital Medical University, Beijing Beijing GoBoard Boren Hospital, Beijing Fu Xing Hospital, Capital Medical University, Beijing Peking Union Medical College Hospital, Beijing Peking University First Hospital, Beijing Peking University Third Hospital, Beijing People's Hospital of Peking University, Beijing The first hospital of Jilin University, Changchun West China School of Medicine, West China Hospital of Sichuan University, Chengdu Xinqiao Hospital of AMU, Chongqing Nanfang Hospital, Southern Medical University, Guangzhou Sun Yat-sen University Cancer Centre, Guangzhou Zhujiang Hospital of Southern Medical University Guangdong, Guangzhou The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou The Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou Qilu Hospital of Shangdong University, Jinan The First Affiliated Hospital of Nanchang University, Nanchang Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing Jiangsu Province Hospital, Nanjing The Affiliated People's Hospital of Ningbo University, Ningbo Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai The First Affiliated Hospital of Soochow University, Suzhou Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjing Tianjin Medical University General Hospital, Tianjing The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University, Zhengzhou